Kringle 5 - Abbott LaboratoriesAlternative Names: Kringle-5 - Abbott
Latest Information Update: 01 Feb 2013
At a glance
- Originator Abbott Laboratories
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Aug 2005 Preclinical trials in Cancer in USA (unspecified route)